Aspiriant LLC Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$66.7M |
| 2 |
iShares MSCI Global Min Vol Factor ETF
ACWV
|
+$42.1M |
| 3 |
iShares US Real Estate ETF
IYR
|
+$39.7M |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$39M |
| 5 |
State Street SPDR Dow Jones International Real Estate ETF
RWX
|
+$31.4M |
Top Sells
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 2.62% |
| 2 | Industrials | 0.5% |
| 3 | Consumer Staples | 0.37% |
| 4 | Energy | 0.26% |
| 5 | Communication Services | 0.21% |
Similar funds
Aspiriant LLC's Q3 2015 Portfolio in Review
As of Q3 2015, Aspiriant LLC held 122 positions worth $1.2B, up 17% from $1.02B the previous quarter. Its ten largest holdings account for 70% of the portfolio.
Aspiriant LLC deployed $290M of net new capital in Q3 2015, opening 8 new positions and adding to 54 existing holdings. Its largest new stake was iShares MSCI Global Min Vol Factor ETF: 608,655 shares worth $40.8M.
By sector, the portfolio is most concentrated in Financials at 2.6% of assets, down from 3.6% a quarter earlier, followed by Industrials and Consumer Staples.
On the sell side, the largest reduction was GS Connect S&P GSCI Enhanced Commodity Total Return Strategy Index ETN (maturity subject to postpone, an estimated $46.3M trimmed.
- Aspiriant LLC's largest Q3 2015 buy was iShares MSCI Global Min Vol Factor ETF: 608,655 shares worth $40.8M.
- Aspiriant LLC added most to iShares Core MSCI Emerging Markets ETF in Q3 2015, an estimated $66.7M increase.
- Aspiriant LLC's biggest Q3 2015 reduction was GS Connect S&P GSCI Enhanced Commodity Total Return Strategy Index ETN (maturity subject to postpone, cutting an estimated $46.3M.
- Aspiriant LLC fully exited Walt Disney in Q3 2015, selling an estimated $1M.
- Aspiriant LLC's ten largest holdings make up 70% of its $1.2B portfolio in Q3 2015.
- Aspiriant LLC opened 8 new positions and closed 17 in Q3 2015.
- Aspiriant LLC's portfolio value rose 17% quarter-over-quarter to $1.2B.
Based on Aspiriant LLC's 13F filing for Q3 2015, filed 9 Nov 2015.